The German pharmaceutical-and-agricultural group stated that the deal goals to enhance its ophthalmology pipeline.
Source link
Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion
Related Posts
China Is Worried AI Threatens Party Rule—and Is Trying to Tame It
Beijing is imposing robust guidelines to make sure chatbots don’t misbehave, whereas hoping to remain aggressive with the U.S. Source…
I Used Google’s New Gemini-Powered ‘Help Me Create’ Tool in Docs. It’s Great at Corporate-Speak
Google rolled out a number of new AI options at the moment for its core Workspace merchandise: Google Docs, Sheets,…
Anthropic executive on spending, ads, Claude Cowork market sell-off
Anthropic is targeted on rising its enterprise slightly than making “flashy headlines,” its business chief instructed CNBC in a thinly-veiled…